Intellia Therapeutics (NTLA) Operating Leases (2019 - 2025)
Historic Operating Leases for Intellia Therapeutics (NTLA) over the last 7 years, with Q3 2025 value amounting to $70.6 million.
- Intellia Therapeutics' Operating Leases fell 1438.27% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.6 million, marking a year-over-year decrease of 1438.27%. This contributed to the annual value of $190.0 million for FY2024, which is 9633.89% up from last year.
- Latest data reveals that Intellia Therapeutics reported Operating Leases of $70.6 million as of Q3 2025, which was down 1438.27% from $75.6 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Operating Leases ranged from a high of $190.0 million in Q4 2024 and a low of $60.0 million during Q2 2022
- Moreover, its 5-year median value for Operating Leases was $82.4 million (2024), whereas its average is $88.0 million.
- Per our database at Business Quant, Intellia Therapeutics' Operating Leases surged by 32045.62% in 2021 and then crashed by 1858.23% in 2024.
- Intellia Therapeutics' Operating Leases (Quarter) stood at $64.9 million in 2021, then surged by 75.65% to $114.0 million in 2022, then fell by 15.15% to $96.7 million in 2023, then soared by 96.34% to $190.0 million in 2024, then crashed by 62.84% to $70.6 million in 2025.
- Its last three reported values are $70.6 million in Q3 2025, $75.6 million for Q2 2025, and $80.5 million during Q1 2025.